Illumina's Q3 Revenues Jump 25 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third quarter revenues increased 25 percent year over year, beating Wall Street estimates on the top and bottom line.

The San Diego-based genetic analysis tools firm reported total revenues of $357 million, up from $285.9 million for Q3 2012, and surpassing the Wall Street consensus estimate for revenues of $343.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.